Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Bemnifosbuvir-Ruzasvir · 2 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| Bemnifosbuvir - Ruzasvir (BEM/RZR) | EXPERIMENTAL | - |
| Sofosbuvir-Velpatasvir (SOF/VEL) | ACTIVE_COMPARATOR | - |
| Bemnifosbuvir-Ruzasvir (BEM/RZR) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Bemnifosbuvir-Ruzasvir | DRUG | BEM/RZR Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 8 weeks (in those without cirrhosis) or 12 weeks (in those with compensated cirrhosis) |
| Sofosbuvir-Velpatasvir | DRUG | SOF/VEL Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 12 weeks |
| Bemnifosbuvir-Ruzasvir (BEM/RZR) | DRUG | BEM/RZR Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 8 weeks (in those without cirrhosis) or 12 weeks (in those with compensated cirrhosis) |
| Sofosbuvir-Velpatasvir (SOF/VEL) | DRUG | SOF/VEL Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 12 weeks |
Key Inclusion Criteria: * Use of adequate contraception for females of childbearing potential * Must be direct-acting antiviral (DAA)-treatment-naïve (never exposed to an approved or experimental DAA for HCV) * Documented medical history compatible with chronic HCV * Either no liver cirrhosis or wi...
Bemnifosbuvir-Ruzasvir (BEM/RZR) is an investigational small molecule being developed for the treatment of chronic hepatitis C virus (HCV) infection. It is currently in Phase 3 clinical development and has received Fast Track designation from the FDA.
Bemnifosbuvir-Ruzasvir targets the hepatitis C virus (HCV). It is a small molecule antiviral designed to treat chronic HCV infection by acting on the virus itself.
Bemnifosbuvir-Ruzasvir is being developed by Atea Pharmaceuticals, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol AVIR.
Bemnifosbuvir-Ruzasvir is in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA. It has received Fast Track designation for the treatment of chronic hepatitis C virus infection.
Bemnifosbuvir-Ruzasvir is being studied in two active Phase 3 trials: NCT07037277 (C-Forward) and NCT06868264 (C-BEYOND). Both are active but not recruiting, with 880 participants each, comparing BEM/RZR to sofosbuvir/velpatasvir (SOF/VEL) in patients with chronic HCV.
Yes, Bemnifosbuvir-Ruzasvir is also known as BEM/RZR. The combination is referred to by this shortened name in clinical trial documentation and research contexts.